Who are Scenesse's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Acthar Gel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/afamelanotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Scenesse — Competitive Intelligence Brief

Scenesse (AFAMELANOTIDE) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: afamelanotide. Area: Rare Disease.

marketed afamelanotide Melanocyte-stimulating hormone receptor Rare Disease Recombinant protein Live · refreshed every 30 min

Target snapshot

Scenesse (AFAMELANOTIDE) — Clivunel Inc.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Scenesse TARGET	AFAMELANOTIDE	Clivunel Inc	marketed	afamelanotide	Melanocyte-stimulating hormone receptor	2019-01-01
Acthar Gel	CORTICOTROPIN	Mallinckrodt Ireland	marketed	Adrenocorticotropic Hormone [EPC]	Melanocyte-stimulating hormone receptor	1950-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2041-07-18 — Acthar Gel · 11752199 · Method of Use · US
2043-10-27 — Acthar Gel · 12440542 · Formulation · US
2043-10-27 — Acthar Gel · 12102662 · Method of Use · US
2043-10-27 — Acthar Gel · 12233105 · Method of Use · US
2043-10-27 — Acthar Gel · 11975047 · Method of Use · US
2043-10-27 — Acthar Gel · 12324787 · Formulation · US

Sponsor landscape (afamelanotide class)

Clivunel Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Scenesse — Competitive Intelligence Brief. https://druglandscape.com/ci/afamelanotide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab